Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial | Zendy

Jeanne Marrazzo | Zendy; Julia C. Dombrowski | Zendy; Michael R. Wierzbicki | Zendy; Charlotte Perlowski | Zendy; Angela Pontius | Zendy; Dwyn Dithmer | Zendy; Jane R. Schwebke | Zendy

Open Access

Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial

Author(s) -

Jeanne Marrazzo,

Julia C. Dombrowski,

Michael R. Wierzbicki,

Charlotte Perlowski,

Angela Pontius,

Dwyn Dithmer,

Jane R. Schwebke

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy554

Subject(s) - medicine , bacterial vaginosis , adverse effect , randomized controlled trial , vaginal discharge , clinical trial , surgery , gynecology

Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) present serious reproductive health risks and management challenges, with poor control attributed to survival of treatment-resistant biofilm communities. Boric acid is used in various regimens for non-albicans VVC and recurrent BV. We investigated safety and efficacy of a novel boric acid-based vaginal anti-infective with enhanced antibiofilm activity (TOL-463) in treating BV and VVC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research